US FDA clears Wyeth hemophilia treatment

WASHINGTON, Feb 21 (Reuters) - U.S. regulators on Thursday cleared a new drug made by Wyeth WYE.N. to treat the blood-clotting disorder hemophilia.

The Food and Drug Administration said it licensed Wyeth's Xyntha anti-hemophilic factor, a genetically engineered form of a protein expressed in the blood, to control and prevent bleeding in patients with hemophilia type A. (Reporting by Kim Dixon; editing by Jeffrey Benkoe)